B2M and neoplasm: Treatment of ranolazine increased the expression of interferons and genes involved in antigen presentations, such as B2M and TAP1. This raises concerns that the increase in polyamine increases tumor immunogenicity, and conversely, inhibition of polyamine biosynthesis may render tumor cells less immunogenic, thereby making tumor more refractory to immune checkpoint blockade.